Sunday, 23 April 2017

Dichloroacetate (DCA) for EGFRvIII positive glioma/glioblastoma

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma


"Immunocytochemistry experiments conducted on EGFRvIIIR cells revealed intense co-localization of PDK1 and EGFRvIII suggesting that PDK1 function is especially relevant for targeting the EGFRvIIIR-dependent GBMs."

"Mouse GBM xenografts tumor cells exhibited heterogeneous labeling of PDK1/EGFRvIII, with positive areas of staining detected alongside negative ones and the DCA treated tumors showed with very low PDK1/EGFRvIII (Figure 6C). Survival curves plotted revealed that DCA treatment increased the survival rate by more than 5 weeks in EGFRvIII treated mice and 3 weeks in EGFRvIIIR treated mice."






3 comments:

  1. Note that this study is referring to PDK1, as in pyruvate dehydrogenase kinase 1, a known target to DCA, not to be confused with PDK1 (gene name: PDPK1) as in phosphoinositide-dependent kinase 1, a kinase that phosphorylates AKT as part of the PI3K/Akt pathway.

    ReplyDelete
  2. Stephen, I'm so sorry for hijacking this thread too, but I'm rather desperate. Is there any boswellia serrata tablet that can be crushed? Or a capsule that can be opened up so its contents dissolve in water? I've only come across soft gel capsules which can't be broken up. I can't find any syrup either.

    ReplyDelete
    Replies
    1. I reposted this for you as a separate post.

      Delete